FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968598970> ?p ?o ?g. }

• W2968598970 endingPage "1108" @default.
• W2968598970 startingPage "1101" @default.
• W2968598970 abstract "Background Outpatient parenteral antibiotic therapy after hospital admission is increasingly popular, but its use to avoid admission to hospital altogether by treating patients wholly as outpatients remains uncommon in children. One reason for the low use of treatment at home is the scarcity of evidence of its cost-effectiveness. In this planned follow-up analysis of the Cellulitis at Home or Inpatient in Children from the Emergency Department (CHOICE) trial, we aimed to assess the cost-effectiveness of an admission avoidance pathway, in which children were treated at home, compared with standard hospital care for the intravenous treatment of moderate or severe cellulitis. Methods We did a cost-effectiveness analysis to compare home treatment with intravenous ceftriaxone versus hospital treatment with intravenous flucloxacillin in children aged 6 months to 18 years who had presented to the emergency department at The Royal Children's Hospital, Melbourne, VIC, Australia, with moderate or severe uncomplicated cellulitis. We included costs from two sources: institutional costs at a patient level and expenses incurred by families. We measured effectiveness with quality-adjusted life years (QALYs), which we derived from the Child Health Utility 9D questionnaire, and a clinical outcome of treatment failure, which was the primary outcome of the CHOICE trial. We planned to calculate the incremental cost-effectiveness ratio, defined as the difference between groups in total cost divided by the difference between groups in effectiveness. The CHOICE trial is registered at ClinicalTrials.gov, number NCT02334124. Findings We included 180 children who comprised the per-protocol population in the CHOICE trial: 89 children in the home group and 91 children in the hospital group. The institutional cost per patient per episode was significantly lower in the home group than in the hospital group (AUS$1965 vs $3775; p<0·0001). The mean cost incurred per family was $182 for the home group and $593 for the hospital group (p<0·0001). Both measures of effectiveness were significantly better in the home group than in the hospital group: QALYs were 0·005 for the home group versus 0·004 for the hospital group (p<0·0001), and treatment failure occurred in one (1%) patient in the home group versus seven (8%) patients in the hospital group (risk difference −6·5%, 95% CI −12·4 to −0·7; p=0·029). Calculating the incremental cost-effectiveness ratio was thus deemed redundant. Interpretation Treatment at home was less costly and more effective than standard hospital care for children with moderate or severe cellulitis. These findings support development of this admission avoidance pathway in hospitals. Funding The Royal Children's Hospital Foundation, Murdoch Children's Research Institute." @default.
• W2968598970 created "2019-08-22" @default.
• W2968598970 creator A5019209954 @default.
• W2968598970 creator A5024387414 @default.
• W2968598970 creator A5033166682 @default.
• W2968598970 creator A5049394027 @default.
• W2968598970 creator A5078953009 @default.
• W2968598970 creator A5086528283 @default.
• W2968598970 date "2019-10-01" @default.
• W2968598970 modified "2023-10-16" @default.
• W2968598970 title "Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis" @default.
• W2968598970 cites W1947485284 @default.
• W2968598970 cites W1986111824 @default.
• W2968598970 cites W2007373992 @default.
• W2968598970 cites W2010391006 @default.
• W2968598970 cites W2018995282 @default.
• W2968598970 cites W2036162952 @default.
• W2968598970 cites W2050859703 @default.
• W2968598970 cites W2084457650 @default.
• W2968598970 cites W2084979444 @default.
• W2968598970 cites W2119591129 @default.
• W2968598970 cites W2127656822 @default.
• W2968598970 cites W2129458535 @default.
• W2968598970 cites W2143025931 @default.
• W2968598970 cites W2143532751 @default.
• W2968598970 cites W2149825837 @default.
• W2968598970 cites W2169192244 @default.
• W2968598970 cites W2203291380 @default.
• W2968598970 cites W2234055984 @default.
• W2968598970 cites W2334824862 @default.
• W2968598970 cites W2369846359 @default.
• W2968598970 cites W2744875117 @default.
• W2968598970 cites W2750316786 @default.
• W2968598970 cites W2764150528 @default.
• W2968598970 cites W2797186942 @default.
• W2968598970 cites W2919906145 @default.
• W2968598970 cites W4236430536 @default.
• W2968598970 doi "https://doi.org/10.1016/s1473-3099(19)30288-9" @default.
• W2968598970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31420292" @default.
• W2968598970 hasPublicationYear "2019" @default.
• W2968598970 type Work @default.
• W2968598970 sameAs 2968598970 @default.
• W2968598970 citedByCount "20" @default.
• W2968598970 countsByYear W29685989702019 @default.
• W2968598970 countsByYear W29685989702020 @default.
• W2968598970 countsByYear W29685989702021 @default.
• W2968598970 countsByYear W29685989702022 @default.
• W2968598970 countsByYear W29685989702023 @default.
• W2968598970 crossrefType "journal-article" @default.
• W2968598970 hasAuthorship W2968598970A5019209954 @default.
• W2968598970 hasAuthorship W2968598970A5024387414 @default.
• W2968598970 hasAuthorship W2968598970A5033166682 @default.
• W2968598970 hasAuthorship W2968598970A5049394027 @default.
• W2968598970 hasAuthorship W2968598970A5078953009 @default.
• W2968598970 hasAuthorship W2968598970A5086528283 @default.
• W2968598970 hasConcept C112930515 @default.
• W2968598970 hasConcept C118552586 @default.
• W2968598970 hasConcept C141071460 @default.
• W2968598970 hasConcept C168563851 @default.
• W2968598970 hasConcept C187212893 @default.
• W2968598970 hasConcept C194828623 @default.
• W2968598970 hasConcept C2776520383 @default.
• W2968598970 hasConcept C2777238321 @default.
• W2968598970 hasConcept C2778355172 @default.
• W2968598970 hasConcept C2779489039 @default.
• W2968598970 hasConcept C2780724011 @default.
• W2968598970 hasConcept C2908647359 @default.
• W2968598970 hasConcept C3019080777 @default.
• W2968598970 hasConcept C501593827 @default.
• W2968598970 hasConcept C515549039 @default.
• W2968598970 hasConcept C523546767 @default.
• W2968598970 hasConcept C54355233 @default.
• W2968598970 hasConcept C71924100 @default.
• W2968598970 hasConcept C86803240 @default.
• W2968598970 hasConcept C89423630 @default.
• W2968598970 hasConcept C99454951 @default.
• W2968598970 hasConceptScore W2968598970C112930515 @default.
• W2968598970 hasConceptScore W2968598970C118552586 @default.
• W2968598970 hasConceptScore W2968598970C141071460 @default.
• W2968598970 hasConceptScore W2968598970C168563851 @default.
• W2968598970 hasConceptScore W2968598970C187212893 @default.
• W2968598970 hasConceptScore W2968598970C194828623 @default.
• W2968598970 hasConceptScore W2968598970C2776520383 @default.
• W2968598970 hasConceptScore W2968598970C2777238321 @default.
• W2968598970 hasConceptScore W2968598970C2778355172 @default.
• W2968598970 hasConceptScore W2968598970C2779489039 @default.
• W2968598970 hasConceptScore W2968598970C2780724011 @default.
• W2968598970 hasConceptScore W2968598970C2908647359 @default.
• W2968598970 hasConceptScore W2968598970C3019080777 @default.
• W2968598970 hasConceptScore W2968598970C501593827 @default.
• W2968598970 hasConceptScore W2968598970C515549039 @default.
• W2968598970 hasConceptScore W2968598970C523546767 @default.
• W2968598970 hasConceptScore W2968598970C54355233 @default.
• W2968598970 hasConceptScore W2968598970C71924100 @default.
• W2968598970 hasConceptScore W2968598970C86803240 @default.
• W2968598970 hasConceptScore W2968598970C89423630 @default.
• W2968598970 hasConceptScore W2968598970C99454951 @default.
• W2968598970 hasIssue "10" @default.

• next